Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drug Safety
Erschienen in: Drug Safety 11/2001

01.09.2001 | Review Article

The Use of Analgesics in Patients with Asthma

verfasst von: Dr Sarah Levy, Glyn Volans

Erschienen in: Drug Safety | Ausgabe 11/2001

Einloggen, um Zugang zu erhalten

Abstract

Aspirin (acetylsalicylic acid) and other nonsteroidal anti-inflammatory drugs (NSAIDs) cause deterioration in respiratory function in approximately 10% of adults with asthma and a smaller proportion of children with asthma.
We propose evidence-based guidelines for the safe use of NSAIDs in individuals with asthma following systematic review of data from the last 10 years relevant to the use of these drugs in such patients.
We would currently recommend that patients with asthma who are known to be intolerant of NSAIDs or who exhibit any of the high risk clinical features for intolerance to these drugs (severe asthma, nasal polyps or chronic rhinosinusitis) should use NSAIDs only under close medical supervision. In those with high risk features formal aspirin provocation testing would be recommended prior to the therapeutic use of NSAIDs. Those individuals with asthma who regularly use NSAIDs can continue to do so but should be warned that intolerance to NSAIDs can develop late in life. Lack of relevant experimental evidence precludes the production of evidence-based guidelines for the group of patients with asthma who do not exhibit high risk clinical features and who have never before used NSAIDs. We would currently recommend that this group be treated as potentially intolerant to NSAIDs and use of these drugs can only be recommended under medical supervision but note that further studies and clinical experience could be expected to relax this restriction for many patients.
Recent data have suggested that frequent use of paracetamol (acetaminophen) may contribute to a deterioration of respiratory function in asthma. A small proportion of patients with asthma who are NSAID-intolerant experience short-lived deterioration in respiratory function with the use of high doses of paracetamol but this is uncommon and has not been implicated in life-threatening reactions. Routine warnings about paracetamol use in asthma are, therefore, not warranted. Medical personnel, however, should be aware of the potential for worsening of symptoms in some individuals with asthma using paracetamol and institute formal investigation or withdrawal of the drug if they suspect such a reaction.
Literatur
1.
Shaheen SO, Sterne JA, Songhurst CE, et al. Frequent paracetamol use and asthma in adults. Thorax 2000; 55: 266–70PubMedCrossRef
2.
Raghuram A. Paracetamol and asthma [letter]. Thorax 2000; 55: 883PubMed
3.
Mudge D. Paracetamol and asthma [letter]. Thorax 2000; 55: 883–4PubMed
4.
5.
6.
7.
8.
9.
Schiavino D, Nucera E, Milani A, et al. The aspirin disease. Thorax 2000; 55Suppl. 2: S66–S69PubMedCrossRef
10.
Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 2000; 55Suppl. 2: S42–S44PubMedCrossRef
11.
Marquette CH, Saulnier F, Leroy O, et al. Long term prognosis for near fatal asthma: a 6 year follow up study of 145 asthmatic patients who underwent mechanical ventilation fore a near fatal attack of asthma. Am Rev Respir Dis 1992; 146: 76–81PubMed
12.
Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000 Sep; 16(3): 432–6PubMedCrossRef
13.
Estrada Rodriguez JL, Florido Lopez JF, Belchi Hernandez JB, et al. Asthma in children and ASA intolerance. J Investig Allergol Clin Immunol 1993; 3(6): 315–20PubMed
14.
Settipane GA, Chafee FH, Klein DE. Aspirin intolerance II: a prospective study in an atopic and normal population. J Allergy Clin Immunol 1974; 53: 200–4PubMedCrossRef
15.
Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and COAD in a population based study. Int J Epidemiol 1999; 28: 717–22PubMedCrossRef
16.
Szczeklik A, Gryglewski R, Czerniawska-Mysik G, et al. Aspirin induced asthma: hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymatic preparations. J Allergy Clin Immunol 1975; 58(1 Pt 1): 10–8
17.
Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96: 480–5PubMedCrossRef
18.
Beasley R, Crane J, Lai CK, et al. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000 Feb; 105(2 Pt 2): S466–S472PubMedCrossRef
19.
Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996 Apr; 9 (4): 687–95
20.
Kent Kwoh C, Feinstein AR. Rates of sensitivity reactions to aspirin: problems in interpreting the data. Clin Pharmacol Ther 1986; 40: 494–505CrossRef
21.
Rachelefsky GS, Coulson A, Siegel SC, et al. Aspirin intolerance in chronic childhood asthma detected by oral challenge. Pediatrics 1975; 56(3): 443–8PubMed
22.
Reye syndrome update. FDA Drug Bull 1985 Dec; 15 (4): 40
23.
24.
Lesko SM, Allen AA. Asthma morbidity following short-term use of acetaminophen and ibuprofen in asthmatic children [abstract]. Pharmacoepidemiol Drug Saf. 1995; 4Suppl.: S43
25.
Bosso JV, Creighton D, Stevenson DD. Flurbiprofen (ansaid) cross sensitivity in an aspirin sensitive asthmatic patient [letter]. Chest 1992; 101: 856–8PubMedCrossRef
26.
Tanaka H, Nakahara K, Sakai S, et al. A case of aspirin-induced asthma due to ketoprofen adhesive agent. Nihon Kyobu Shikkan Gakkai Zasshi 1992 Apr; 30(4): 653–7PubMed
27.
Watanabe T, Sakata M, Shimabukuro R, et al. Loxoprofen: another NSAID associated with acute asthmatic death. J Toxicol Clin Toxicol 1993; 31(2): 333–40PubMedCrossRef
28.
Chen AH, Bennett CR. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesth Prog 1994; 41(4): 102–7PubMed
29.
Antonicelli L, Tagliabracci A. Asthma death induced by ibuprofen. Monaldi Arch Chest Dis 1995; 50(4): 276–8PubMed
30.
Chan TY. Severe asthma attacks precipitated by NSAIDS [letter]. Ann Pharmacother 1995 Feb; 29(2): 199PubMed
31.
Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996 Jun; 103(6): 890–2PubMed
32.
Sharir M. Exacerbation of asthma by topical diclofenac. Arch Opthalmol 1997 Feb; 115: 294–5CrossRef
33.
Hailemeskel B, Namanny MD, Metzger SD. Severe asthmatic reaction to contraindicated anti-inflammatory drug. Am J Health Syst Pharm 1997 Jan 15; 54(2): 199–200PubMed
34.
35.
Ayres JG, Fleming DM, Whittington RM. Asthma death due to ibuprofen. Lancet 1987 May 9; I: 1082CrossRef
36.
Henochowicz S. Acetaminophen induced asthma in a patient with aspirin idiosyncrasy [letter]. Immunol Allergy Pract 1986; 8: 43
37.
Settipane RA, Stevenson DD. Cross sensitivity with acetaminophen in aspirin sensitive subjects with asthma. J Allergy Clin Immunol 1989; 84: 26–33PubMedCrossRef
38.
Warner T, Giuliano F, Vojnovic I, et al. Non steroid drug selectivity for cycloxygenase-1 correlate with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563–8PubMedCrossRef
39.
Senna GE, Passalacqua G, Andri G, et al. Nimesulide in the treatment of patients intolerant to aspirin and other NSAIDs. Drug Saf 1996; 14: 94–103PubMedCrossRef
40.
Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001 Jul; 108(1 Pt 1): 47–51PubMedCrossRef
41.
Sousa AR, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX 2) in asthmatic airways and its cellular distribution in aspirin sensitive asthmatics. Thorax 1997; 52: 940–5PubMedCrossRef
42.
Flower RJ, Vane JR. Inhibition of prostaglandin synthase in brain explains the antipyretic activity of paracetamol. Nature 1972; 240: 410–1PubMedCrossRef
43.
Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993 Dec 15; 90(24): 11693–7PubMedCrossRef
44.
45.
Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994 Dec; 94(6 Pt 1): 1046–56PubMedCrossRef
46.
Szczeklik A, Sladek A, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin sensitive asthmatics. Am J Respir Crit Care Med 1996; 154: 1608–14PubMed
47.
Christie PE, Smith CM, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9PubMed
48.
Daffern PJ, Muilenburg D, Hugli TE, et al, Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999 Sep; 104(3 Pt 1): 559–64PubMedCrossRef
49.
Cowburn AS, Sladek K, Soja J, et al. Over expression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin intolerant asthma. J Clin Invest 1998; 101: 1–13CrossRef
50.
Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991 Oct; 144(4): 957–8PubMedCrossRef
51.
Lang DM. Antileukotriene agents and aspirin-sensitive asthma: are we removing the second bassoonist or skating to where the puck is gonna be? Ann Allergy Asthma Immunol 2000 Jul; 85(1): 5–8PubMedCrossRef
52.
Stevenson DD. Desensitisation of aspirin sensitive asthmatics: a therapeutic alternative? J Asthma 1983; 20Suppl. 1: 31–8PubMedCrossRef
53.
Pleskow WW, Stevenson DD, Mathison DA et al. Aspirin desensitization in aspirin sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982 Jan; 69(1 Pt 1): 9–11
54.
Stevenson DD. Desensitisation in aspirin induced asthma. In: Szczeklik A, Gryglewski R, Vane J, editors. Eicosanoids, aspirin and asthma. New York (NY): Marcel Dekker, 1998: 523–37
55.
Kowalski ML. Management of aspirin sensitive rhinosinusitis-asthma syndrome; what role for aspirin desensitization?. Allergy Proc 1992 Jul-Aug; 13(4): 175–84PubMedCrossRef
56.
Smith CM, Hawksworth RJ, Thien FC, et al. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 1992 Jun; 5(6): 693–9PubMed
57.
Sanak M, Simon HU, Szczeklik A. Leukotriene C synthase promoter polymorphism and risk of aspirin induced asthma. Lancet 1997; 350: 1599–600PubMedCrossRef
58.
Milewski M, Mastalerz L, Nizankowska E, et al. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998 May; 101(5): 581–6PubMedCrossRef
59.
Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000 May; 15(5): 863–9PubMedCrossRef
60.
Pawlowicz A, Williams WR, Davies BH. Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. Allergy 1991 Aug; 46(6): 405–9PubMedCrossRef
61.
Shaw H, Steans A, Lott D, et al. Asthma and analgesics: a treatment algorithm [abstract]. British Thoracic Society Winter Meeting 2001; 2001 Dec 5-7; London
Metadaten
Titel
The Use of Analgesics in Patients with Asthma
verfasst von
Dr Sarah Levy
Glyn Volans
Publikationsdatum
01.09.2001
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 11/2001
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124110-00004

Weitere Artikel der Ausgabe 11/2001

Drug Safety 11/2001 Zur Ausgabe

Original Research Article

Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease

Review Article

A Risk-Benefit Assessment of Treatments for Infantile Spasms

Leading Article

Nitric Oxide—Releasing NSAIDs

Original Research Article

Parenteral Drug Administration Errors by Nursing Staff on an Acute Medical Admissions Ward During Day Duty

Current Opinion

Causality Assessment of Adverse Effects

Practical Drug Safety

Preventing and Managing Drug-Induced Anaphylaxis